Background and Objective Human carboxylesterase-1 (CES1) and human carboxylesterase-2 (CES2) play an important role in metabolizing many medications. Alcohol is a known inhibitor of these enzymes but the relative effect on CES1 and CES2 is unknown. The aim of this study was to determine the impact of alcohol on the metabolism of specific probes for CES1 (oseltamivir) and CES2 (aspirin). Methods The effect of alcohol on CES1-and CES2-mediated probe drug hydrolysis was determined in vitro using recombinant human carboxylesterase. To characterize the in vivo effects of alcohol, healthy volunteers received each probe drug alone and in combination with alcohol followed by blood sample collection and determination of oseltamivir, aspirin, and respective metabolite pharmacokinetics. Results Alcohol significantly inhibited oseltamivir hydrolysis by CES1 in vitro but did not affect aspirin metabolism by CES2. Alcohol increased the oseltamivir area under the plasma concentration-time curve (AUC) from 0 to 6 h (AUC 0 ? 6 h ) by 27 % (range 11-46 %, p = 0.011) and decreased the metabolite/oseltamivir AUC 0 ? 6 h ratio by 34 % (range 25-41 %, p \ 0.001). Aspirin pharmacokinetics were not affected by alcohol.
Introduction
Mammalian carboxylesterases (CES) are a multigene family of enzymes that catalyze the hydrolysis of endogenous and exogenous compounds containing ester, amide, thioester, or carbamate structures [1] [2] [3] . These enzymes are classified into five main groups, although the majority of CESs involved in xenobiotic transformation are CES1 and CES2 [3] . In humans, CES1 and CES2, expressed primarily in the liver and intestine (proximal expression higher than distal), respectively, play an important role in the biotransformation of diverse classes of commonly used drugs containing ester groups such as clopidogrel, dabigatran, irinotecan, methylphenidate, cocaine, ACE inhibitors, lovastatin, and oseltamivir [2, 4, 5] . Though specific compounds are often susceptible to hydrolysis by both CES1 and CES2, usually only one carboxylesterase serves as the primary pathway. In general, substrates with a small alcohol group and a large acyl group are hydrolyzed by CES1 (e.g., oseltamivir, clopidogrel, methylphenidate, trandolapril) while substrates with large alcohol groups and small acyl groups are preferentially hydrolyzed by CES2 (e.g., prasugrel, irinotecan) [6, 7] . Given their high levels of expression and activity in the liver and intestine, both of these enzymes are important determinants of the first-pass metabolism and disposition of substrate drugs. Thus, factors affecting the catalytic activity of CES1 and CES2 could markedly alter the disposition and the subsequent efficacy and safety of these agents.
One key factor potentially affecting CES1 and CES2 activity is drug-drug interactions that inhibit CES function. The importance of inhibition of drug metabolism in medication safety and efficacy is well established for drugs that undergo metabolism by cytochrome P450 enzymes [8, 9] . In distinct contrast, relatively little is known about the potential for CESs to serve as targets for metabolic inhibition. Alcohol (ethanol) is the most extensively studied CES inhibitor, though most of this research focused on the interaction between cocaine and alcohol. Alcohol inhibits CES-mediated cocaine hydrolysis and results in formation of the pharmacologically active cocaine metabolite, cocaethylene via CES1 [10] [11] [12] [13] . The limited number of human studies of alcohol-mediated inhibition of CESs also concentrated on the cocaine-alcohol interaction and, consistent with the in vitro and animal model findings, show that alcohol inhibits cocaine hydrolysis [14] [15] [16] [17] . However, cocaine was given by non-oral routes so the impact of alcohol on first-pass metabolism could not be determined. In a canine model, cocaine oral bioavailability increased 300 % (0.18-0.72) after alcohol co-administration suggesting that alcohol doses within the normal range of human consumption could significantly inhibit CES activity [11] . However, because cocaine is hydrolyzed by both CES1 and CES2, the relative contribution of inhibition of each enzyme to the observed interaction is uncertain [18, 19] . In the only human studies involving a CES substrate drug other than cocaine, alcohol inhibited the CES1-mediated hydrolysis of oral methylphenidate resulting in increased methylphenidate exposure [20] [21] [22] .
Collectively, these findings suggest that all CES substrate medications could be vulnerable to this drug interaction with alcohol, resulting in important changes in drug disposition. However, because of inherent limitations of the in vitro and animal models, the applicability of these results to the clinical use of other CES substrate drugs in humans remains problematic [23, 24] . Furthermore, whether alcohol inhibits CES2 in humans is unknown. Understanding the effects of alcohol on the activity of these enzymes in humans has important implications given the growing number of medications metabolized by these enzymes and the widespread consumption of alcohol.
Therefore, the purpose of this study was to determine the effects of alcohol on the in vitro hydrolysis and pharmacokinetics of probe drugs specific for CES1 (oseltamivir) and CES2 (aspirin) activity in healthy volunteers.
Methods

In vitro Inhibition of Oseltamivir and Aspirin
Hydrolysis by Alcohol
The effect of alcohol on CES1-mediated oseltamivir hydrolysis was determined using recombinant human carboxylesterase-1b (CES1) (BD Supersomes TM ; BD Gentest, San Jose, CA, USA). The incubations were performed in duplicate at 37°C in 96-well cluster plates with a total assay volume of 100 lL in each well with a final protein concentration of 0.05 mg/mL. The assay buffer was 0.1 M potassium phosphate, pH 7.4, and incubation times were 15 min. The initial oseltamivir concentrations in the incubations were 2 lM. Under these conditions, formation of the oseltamivir carboxylate (product of CES1 hydrolysis) was linear. Oseltamivir was mixed with alcohol at increasing concentrations (0, 12.5, 25, 50, 100, and 200 mM) in the incubation tubes and then recombinant CES1 was added to initiate the reaction. The reaction was terminated by adding an equal volume of ice-cold acetonitrile containing 200 nM internal standard (oseltamivir-d3 and oseltamivir carboxylate-d3). After centrifugation at 16,0009g for 5 min, 10 lL of supernatant was injected onto the liquid chromatography-tandem mass spectrometry (LC-MS/MS) system for determination of oseltamivir and oseltamivir carboxylate concentrations [25] . The half maximal inhibitory concentration (IC 50 ) of alcohol (inhibiting the hydrolysis of oseltamivir to oseltamivir carboxylate) was calculated with GraphPad Prism (version 5.0; GraphPad Software Inc., San Diego, CA, USA).
The effect of alcohol on aspirin hydrolysis by CES1 and CES2 was determined using recombinant human CES1 and CES2 (BD Supersomes TM ). The final protein concentrations for CES1 and CES2 were 0.25 and 0.05 mg/mL, respectively. Incubations were conducted at 37°C in duplicate in 96-well cluster tubes with a total assay volume of 100 lL in each well. The assay buffer was 0.1 M potassium phosphate (pH 7.4), and incubation times were 30 and 15 min for CES1 and CES2, respectively. Substrate (aspirin) concentrations in the incubations were 100 lM. Under these incubation conditions, salicylic acid metabolite formation was linear. Aspirin was mixed with alcohol at increasing concentrations (0, 12.5, 25, 50, 100, and 200 mM) in the incubation tubes and then CES enzyme was added to initiate the reaction. The reaction was terminated by the addition of 200 lL of ice-cold acetonitrile containing 20 lM internal standards (acetylsalicylic acidd4 and salicylic acid-d4). After centrifugation at 16,0009g for 5 min, 10 lL of supernatant was injected onto the LC-MS/MS system for determination of aspirin and salicylic acid concentrations.
Clinical Study
The clinical study was approved by the University of Tennessee Health Science Center (UTHSC) Institutional Review Board and all subjects provided written informed consent before participation.
Subjects
Healthy non-smoking volunteers aged 21-45 years of either sex and of any race or ethnicity that were within 20 % of their ideal body weight were recruited from the UTHSC campus. Subject health status was determined by history, physical examination, electrocardiogram, and clinical laboratory analysis (serum chemistry, complete blood count, urine drug screen, and urinalysis). A urine pregnancy test was required for all female subjects at the screening visit and before each study day requiring alcohol administration. Only self-described social drinkers of alcoholic beverages were eligible to participate. All subjects completed a standard screening test for alcohol problems (Michigan Alcohol Screening Test, MAST). If the MAST score was [2, or there was an indication of other substance abuse disorders, the subject was excluded from the study. The volunteers were required to refrain from all medications and herbal or nutritional supplements and alcohol for at least 1 week prior to and during the study. The study was conducted in accordance with the National Institute of Alcohol Abuse and Alcoholism Recommended Council Guidelines on Ethyl Alcohol Administration in Human Experimentation (http://www.niaaa.nih. gov/Resources/ResearchResources/job22.htm).
Study Design
The study was a single-center, prospective, randomized, four-phase, crossover trial. On the morning of each study day, subjects reported to the UTHSC Clinical Research Center after an overnight fast and received breakfast consisting of two slices of toast with margarine and jelly with 8 ounces of skim milk eaten over 15 min. Fifteen minutes after finishing breakfast, each subject completed the following four study phases in random sequence on separate study days with at least a 1-week washout between phases:
1. Oseltamivir 150 mg: subjects drank a volume of orange juice over 15 min that was equivalent to the volume ingested during the alcohol phase below. Fifteen minutes after consuming the orange juice, a single dose of 150 mg (2 9 75 mg capsules) oral oseltamivir phosphate (Tamiflu Ò , Roche Pharmaceuticals, Nutley, NJ, USA) was given with 150 mL water. Blood samples were collected from an indwelling intravenous catheter or direct venipuncture before and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 24 h after the oseltamivir dose. 2. Oseltamivir 150 mg ? alcohol: subjects drank a volume of alcohol (targeted for a blood alcohol concentration of 0.08 g/dL) mixed with orange juice over 15 min followed 15 min later by oral oseltamivir and blood collection as described above. A blood sample for determination of the blood alcohol concentration was collected 30 min after completion of alcohol consumption. 3. Aspirin 650 mg: this phase was conducted identically to the oseltamivir phase above except that after orange juice ingestion, subjects received a single oral dose of non-enteric-coated aspirin (Genuine Bayer Aspirin Ò , Bayer Healthcare, Whippany, NJ, USA) 650 mg (2 9 325 tablets) with 150 mL water. Blood samples were collected before and at 10, 20, 30, 60, and 90 min and 2, 2.5, 3, 4, 5, 6, 7, and 8 h after the aspirin dose. 4. Aspirin 650 mg ? alcohol: this phase was conducted identically to the aspirin phase except that subjects received orange juice mixed with alcohol as described above.
A published algorithm was used to estimate the dose of alcohol required to achieve the target peak blood alcohol concentration of 0.08 g/dL [26] . This blood alcohol concentration is associated with significant inhibition of CES1 activity in humans [21, 22] . The calculated dose was administered as alcohol (95 %) diluted with sufficient orange juice such that the drink contained approximately 20 % alcohol by volume. Subjects remained at the clinical research center (CRC) until the blood alcohol concentration determined by breathalyzer was less than 0.02 g/dL.
Sample Collection
Blood samples for determination of oseltamivir, aspirin, and respective metabolites of interest were collected into Vacutainer Ò gray top tubes (Becton-Dickinson, Franklin Lakes, NJ, USA) containing sodium fluoride and potassium oxalate to slow ex vivo hydrolysis of oseltamivir and aspirin [27, 28] . Plasma was separated in a refrigerated centrifuge and stored at -70°C until analysis. Samples for determination of blood alcohol concentrations were collected into Vacutainer Ò tubes containing EDTA potassium oxalate/sodium fluoride and refrigerated prior to analysis by a local commercial laboratory using gas-LC. The reported linear range for this assay is 0.01-0.4 g/dL.
Oseltamivir and Aspirin Concentration Analysis
The concentrations of oseltamivir and oseltamivir carboxylate in the in vitro study and in human plasma samples were determined by LC-MS/MS as previously described [25] . In brief, analyte concentrations were determined using an AB SCIEX 3000 triple quadrupole mass spectrometer (Redwood City, CA, USA) interfaced via a turbo ion spray (ESI) source with an Agilent 1100 HPLC module (Santa Clara, CA, USA). Mobile phases were methanol/ water, 1:99 (v/v) containing 2.5 mM formic acid for A, and methanol/water, 99:1 (v/v) modified with the same electrolyte for B. A fast gradient chromatographic method was used. The parent-product ion pairs used for multiple reaction monitoring of oseltamivir, oseltamivir carboxylate, oseltamivir-d3 (internal standard), and oseltamivir carboxylate-d3 (internal standard) were m/z 313.4 ? 225.1, 285.3 ? 138.0, 316.4 ? 228.0, and 288.3 ? 200.0, respectively. The plasma samples (30 lL) were precipitated with 100 lL of methanol containing the internal standards at 100 ng/mL. After centrifugation for 8.0 min at 16,0009g, 10 lL of the resulting supernatant was injected onto the LC-MS/MS. The calibration curve was linear over the range of 0.34-1,000 ng/mL. Accuracy was 95-110 % and the precision was 1.8-11.0 %. The same instruments as described above for oseltamivir were used for determining the aspirin and salicylic acid concentrations. The same mobile phases as described above for oseltamivir were used for measuring aspirin and salicylic acid. A 5-min gradient chromatographic method was used. The parent-product ion pairs used for multiple reaction monitoring of aspirin, salicylic acid, aspirin-d4 (internal standard), and salicylic acid-d4 (internal standard) were m/z 179.3 ? 136.5, 137.1 ? 93.0, 183.2 ? 140.8, and 141.2 ? 97.0, respectively. The parameters of the negative ESI were optimized under the above-mentioned chromatographic conditions. The LC eluent was introduced to the ESI source over the period of 2.0-3.0 min at a flow rate of 0.40 mL/min. The plasma samples (30 lL) were precipitated with 200 lL of ice-cold acetonitrile containing the internal standard (aspirin-d4 2 lg/mL, salicylic acid-d4 20 lg/mL). After centrifugation, 2 lL of the supernatant were injected onto the LC-MS/MS. The calibration curves for quantification of analytes in plasma showed good linearity with correlation coefficients [0.99. The withinrun (n = 3) and between-run (n = 3) assay precision for all the analytes was less than 15 %, while the assay accuracy was also satisfactory (85-115 %). The lower limit of quantification was 0.04 and 0.4 lg/mL for aspirin and salicylic acid, respectively. The analytes were stable under the storage and assay conditions and no matrix effects were observed.
Pharmacokinetic Analysis
Pharmacokinetic parameters were determined by standard non-compartmental methods using Kinetica 5.0 (Thermo Fisher Scientific, Philadelphia, PA, USA). The maximum plasma concentration (C max ) and the time to achieve the maximum concentration (t max ) were obtained directly from the observed data. The AUC up to the last measured time point (AUC last ) was calculated using the trapezoidal method. The AUC from time zero to infinity (AUC 0?? ) was generated by extrapolating the AUC last to infinity using the elimination rate constant (k e ) and the last measured concentration.
Statistical Analysis
Using the published pharmacokinetic data [29, 30] , a sample size of 17 subjects was estimated to have a power of at least 90 % to detect at least a 20 % (a = 0.05) change in oseltamivir and aspirin parent drug AUC with alcohol co-administration. The primary endpoints were parent drug (oseltamivir or aspirin) exposure (C max and AUC) for the control compared with the alcohol phase. The geometric means and geometric coefficients of variation were determined for the pharmacokinetic parameters of interest. For t max , the median and range were determined. The geometric mean ratio (alcohol phase/control) and 90 % confidence intervals for C max and AUC were determined. For each probe drug, differences in pharmacokinetic parameters between the alcohol and control phases were determined by paired t-test after the data were logarithmically transformed. Nonparametric tests (paired-sample, Wilcoxon signed rank test) were used to compare the elimination half-life (t ) and t max between the control and alcohol treatments. Statistical significance was defined as p \ 0.05.
Results
In vitro Hydrolysis
The effects of alcohol on the in vitro hydrolysis of oseltamivir and aspirin are shown in Fig. 1 . Alcohol inhibited the hydrolysis of oseltamivir to oseltamivir carboxylate by recombinant CES1-the IC 50 was 23 mM. Alcohol did not affect the CES-mediated hydrolysis of aspirin to salicylic acid by either recombinant CES1 or CES2.
Human Subjects
Eighteen healthy volunteers (nine were male, nine were female, 15 were Caucasian, two were African-American, and one was Asian) completed the study. The mean ± standard deviation (SD) age was 26.4 ± 3.1 years and weight was 71.5 ± 13.3 kg. The mean ± SD alcohol dose was 0.61 ± 0.05 g/kg. Seven subjects reported nausea after receiving oseltamivir in the control phase and one subject vomited approximately 1.5 h after receiving oseltamivir in the control phase. This subject's pharmacokinetic data were excluded from the analysis because oseltamivir exposure was markedly less than that in the other subjects. One subject withdrew from the study because of nausea and headache after receiving oseltamivir in the control phase. No adverse effects related to alcohol consumption were observed.
Effect of Alcohol on Oseltamivir Pharmacokinetics
Oseltamivir and oseltamivir carboxylate metabolite pharmacokinetics with and without co-administration of alcohol are summarized in Table 1 and Fig. 2 . Alcohol (mean ± SD blood alcohol concentration 0.06 ± 0.03 g/ dL) significantly increased the oseltamivir AUC 0 ? 6 h and AUC 0 ? ? by 27 % compared with control P = 0.011 and 0.007, respectively). Although not significant, a trend towards an increase in oseltamivir C max was observed. The oseltamivir elimination half-life and t max were not affected by alcohol co-administration. For the oseltamivir carboxylate metabolite, the t max increased by 50 % (p = 0.011) and the AUC 0 ? 6 h decreased by 16 % (p = 0.015) after alcohol ingestion compared with control. The other oseltamivir carboxylate pharmacokinetic parameters were not affected by alcohol. The oseltamivir carboxylate metabolite/ oseltamivir parent AUC 0 ? 6 h and AUC 0 ? ? ratios were decreased by 34 % (p \ 0.001) and 21 % (p = 0.002), respectively by alcohol administration (Fig. 3) .
Effect of Alcohol on Aspirin Pharmacokinetics
The effects of alcohol (mean ± SD blood alcohol concentration 0.06 ± 0.02 g/dL) on aspirin and salicylic acid pharmacokinetics are summarized in Table 2 and Fig. 4 . Compared with the control phase, alcohol significantly (p = 0.045) increased the aspirin AUC 0 ? 2 h by 37 % but did not affect AUC 0 ? ? . Salicylic acid pharmacokinetics were not affected by alcohol co-administration, although a trend towards an increase in AUC 0 ? 2 h was observed. Alcohol did not change the salicylic acid/aspirin AUC 0 ? 2 h or AUC 0 ? ? ratios.
Discussion
The results from the present study show that alcohol inhibits in vitro CES1-mediated oseltamivir hydrolysis. Consistent with this finding, alcohol co-administration significantly inhibits oseltamivir hydrolysis to the active oseltamivir carboxylate metabolite in human subjects, resulting in increased exposure to the parent oseltamivir and reduction in the oseltamivir carboxylate/oseltamivir AUC ratio. In contrast, alcohol did not inhibit aspirin hydrolysis by CES2 in vitro, although it did increase the early exposure (AUC 0 ? 2 h ) to aspirin in human subjects. However, alcohol did not affect the salicylic acid/aspirin AUC ratio Fig. 1 The effect of alcohol on the in vitro hydrolysis of oseltamivir (a) and aspirin (b) by human recombinant carboxylesterase-1 and carboxylesterase-2, respectively. The formation of oseltamivir carboxylate and salicylic acid under control conditions (no alcohol) is set at 100 %. The incubation times were 15 min for both oseltamivir and aspirin. The half maximal inhibitory concentration for alcohol's inhibition of oseltamivir hydrolysis is 23 mM. Each data point is the mean ± standard deviation of duplicate determinations suggesting that mechanism(s) other than CES2 inhibition are responsible for the initial increases in aspirin plasma concentrations. The in vitro inhibition studies conducted in recombinant human CES1 and CES2 enzymes accurately predicted the effects of alcohol on oseltamivir and aspirin pharmacokinetics in human subjects.
A growing number of medications undergo hydrolysis by CES1 and CES2 [4] . Many clinically used drugs are designed as ester-containing prodrugs to improve oral absorption. These inactive agents require hydrolysis by esterases in the liver or intestine to the active moiety and include such agents as oseltamivir, the antiplatelet agent prasugrel, many ACE inhibitors, and dabigatran etexilate [5, [31] [32] [33] . Because the therapeutic effects of these prodrugs are dependent on efficient conversion to the active form, decreased CES function could impair prodrug activation, resulting in decreased therapeutic effect or potential toxicity from increased exposure to the parent drug [33] [34] [35] . In contrast, for substrate drugs that are pharmacologically active (e.g., cocaine, methylphenidate), esterasemediated hydrolysis usually converts the parent compound to inactive metabolites, and reduced enzyme activity would result in greater drug exposure and increased pharmacological effects [21] . Thus, drug interactions that inhibit the catalytic activity of these enzymes would have a variable effect on drug plasma concentrations and resultant efficacy and safety depending on whether the affected substrate drug is a prodrug or active compound.
Most work on drug interactions involving CES substrate drugs focused on the interaction between cocaine and alcohol because this combination is frequently co-abused. Alcohol decreases cocaine hydrolysis and leads to formation of the pharmacologically active cocaine metabolite, cocaethylene, via CES1-mediated transesterification [17, 36, 37] . However, cocaine is hydrolyzed by both CES1 and CES2 and in vitro data suggest alcohol may also inhibit CES2 [7, 10, 38, 39] . Thus, the specific CES enzyme affected by alcohol remains unclear. Therefore, in this study, we administered probe drugs specific for each enzyme alone and in combination with alcohol to humans to elucidate the mechanism of this interaction.
To determine the effect of alcohol on CES1, we used the influenza virus neuraminidase inhibitor oseltamivir as a probe. Oseltamivir is an ethyl ester prodrug that undergoes hydrolysis almost exclusively by hepatic CES1 to form the active oseltamivir carboxylate metabolite that is primarily eliminated by renal elimination [29, 31, 40] . Oseltamivir is not hydrolyzed by CES2 or CYP450 enzymes, no other metabolites have been identified in humans, and less than 5 % of the parent drug appears unchanged in the urine [29, 31, 40] . Thus, this agent is a suitable in vivo probe for hepatic CES1 activity.
Our results show alcohol increased parent oseltamivir C max and AUC by approximately 20 and 27 %, respectively. Alcohol did not affect oseltamivir elimination halflife; however, this is expected because oseltamivir is a high-extraction hepatically eliminated drug [29, 41] . Thus, alcohol inhibits first-pass metabolism, but does not alter systemic clearance that is liver blood flow dependent. Despite the increase in oseltamivir exposure, oseltamivir carboxylate active metabolite pharmacokinetics were less affected by alcohol. This finding is expected as the only pathway for oseltamivir metabolism is CES1 hydrolysis. The significant decrease in the oseltamivir carboxylate/ oseltamivir AUC ratios indicates that alcohol inhibits the hydrolysis of oseltamivir by hepatic CES1 rather than increasing the absorption of the parent drug. Our observed increases in parent oseltamivir exposure are similar to those reported when oral methylphenidate is co-administered with alcohol [21] . Like the study design used by these investigators [21] , for safety purposes we also administered a single dose of alcohol. Thus, our results likely underestimate the impact of higher alcohol concentrations or multiple alcohol doses on CES1 activity and substrate drug disposition. Our in vitro results showing concentrationdependent effects of alcohol on oseltamivir hydrolysis support this concept. Oseltamivir is now the third CES1 substrate drug, along with cocaine and methylphenidate that is inhibited by alcohol in humans [15, 17, 21] . Collectively, these results suggest that alcohol may interact with all CES1 substrate drugs. However, our recent work showed that alcohol did not affect the in vitro hydrolysis of the oral anticoagulant dabigatran etexilate that is hydrolyzed by both CES1 and CES2 [5] .
In the presence of CES1, alcohol also mediates transesterification of a number of substrate drugs including cocaine, methylphenidate, and clopidogrel [11, 17, 20, 21, 37, 42, 43] . These drugs are methyl esters that, in the presence of alcohol, produce the corresponding ethyl ester metabolite by the CES1-catalyzed exchange of the ester's Fig. 2 Mean ± SEM plasma concentrations of oseltamivir (a) and oseltamivir carboxylate (b) after administration of 150 mg oral oseltamivir phosphate during the control and alcohol phases (n = 17 subjects). The inset figures show the mean ± SEM plasma concentrations over the entire 24-h sampling period. SEM standard error of the mean methyl group with the alcohol's ethyl group (transesterification). In the case of cocaine and methylphenidate, these ethylated metabolites are pharmacologically active [17, 44, 45] . In the present human study, we could not determine if oseltamivir undergoes transesterification similar to these other drugs. The structure of the oseltamivir parent compound contains an ethyl, rather than a methyl ester. Therefore, in the presence of alcohol, the addition of the ethyl group from transesterification would result in reformation of the parent oseltamivir compound. This concept is supported by previous work with the in vitro CES1-mediated hydrolysis of the ethyl esters cocaethylene (transesterified active cocaine metabolite) and CDP323 (investigational agent for treatment of multiple sclerosis) [46, 47] . The impact of this potential regeneration of the oseltamivir parent drug by transesterification on our results is uncertain and requires further study, although the reduction in oseltamivir carboxylate formation supports inhibition of CES1 by alcohol. Importantly, for future studies of the alcohol-CES1 interaction, use of probe drugs that do not contain ethyl ester structures should be considered to avoid this potential confounding effect.
We used aspirin as a probe drug for determining the effect of alcohol on CES2 activity. Aspirin is nearly completely absorbed after oral administration and the bioavailability ranges from 50 to 68 % owing to a high degree of first-pass metabolism. A recent paper found that butyrylcholinesterase is the major responsible enzyme for aspirin hydrolysis in plasma [48] . However, the hydrolysis of aspirin by human plasma was undetectable as compared with efficient hydrolysis in intestinal microsomes [43] . In addition, aspirin hydrolysis to salicylic acid strongly correlates with the level of CES2 expression in intestinal microsomes and the drug is predominately hydrolyzed by CES2 [43, 49] . The majority of aspirin hydrolysis would be Data are expressed as geometric means (geometric coefficients of variation) and t max as median (range). The 90 % confidence intervals for the alcohol/control ratios are shown t elimination half-life, t max time to maximum plasma concentration, C max maximum plasma concentration, AUC 0 ? 2 h area under the plasma concentration-time curve from 0 to 2 h, AUC 0 ? ? area under the plasma concentration-time curve from time 0 to infinity * p \ 0.05 compared with control expected to be mediated by intestinal CES2, supporting the suitability of aspirin as a probe for CES2 [2, 7, 24] . Our in vitro and clinical data suggest that alcohol does not inhibit CES2 activity. In humans, aspirin is rapidly absorbed after oral administration [50] . Once absorbed, it undergoes hydrolysis by several plasma esterases including butyrylcholinseterase, paraoxonase, albumin, and plateletactivating factor acetylhydrolase [48, 51] . Therefore, we focused on the AUC 0 ? 2 h as it would more precisely characterize the effect of alcohol on aspirin hydrolysis by intestinal CES2 because aspirin plasma concentrations at later time points could be affected by plasma esterase activity. Although alcohol increased the aspirin AUC 0 ? 2 h in the study subjects, the salicylic acid/aspirin AUC ratio was not affected by alcohol at any time point. If alcohol inhibits intestinal CES2, then a decrease in the AUC ratio would be expected, as inhibition of the enzyme should result in reduced salicylic acid formation. Thus, the early increase in aspirin plasma concentrations with alcohol is more likely due to other mechanisms (e.g., increased absorption or gastric emptying) other than CES2 inhibition [50, 52] .
The few previous studies on the effect of alcohol on CES2 demonstrate an inconsistent effect on this enzyme's activity. Roberts et al. reported that alcohol inhibited the in vitro formation of the cocaine metabolite ecgonine methyl ester (product of CES2 hydrolysis of cocaine) in human and mouse hepatic microsomes but did not affect in vivo formation of this metabolite in mice [38] . Similarly, another study showed that alcohol inhibits the hydrolysis of p-aminobenzoic acid esters by recombinant CES2 [7] . In contrast, Dean et al. [10] found that alcohol did not affect the formation of ecgonine methyl ester in human liver. In a recent study from our laboratory, alcohol failed to inhibit Fig. 4 Mean ± SEM plasma concentrations of aspirin (a) and salicylic acid (b) after administration of 650 mg oral aspirin during the control and alcohol phases (n = 18 subjects). The inset panels show the mean ± SEM plasma concentrations over the entire 8-h sampling period. SEM standard error of the mean in vitro CES2-mediated hydrolysis of dabigatran etexilate [5] . Further, we also showed that although alcohol did reduce formation of ecgonine methyl ester from cocaine by recombinant CES2, it did so only at supraphysiologic concentrations [5] . Thus, the results from the present in vitro and clinical study, combined with the previous work by other investigators, suggest that alcohol is unlikely to significantly affect CES2 activity and result in a clinically significant drug interaction, although we are unable to rule out potential effects on other CES2 substrate drugs.
Limitations of our study should be noted. Our goal in this project was to conduct a mechanistic analysis of the alcohol-carboxylesterase drug interaction. Oseltamivir is a specific CES1 substrate with no significant alternate metabolic pathways that we chose as a probe drug to avoid the confounding effects of competing metabolic pathways. Thus, inhibition of CES1 because of alcohol does not, as we demonstrated, reduce the systemic exposure (AUC 0 ? ? ) to the active carboxylate metabolite formed by CES1 hydrolysis. The conclusion is that alcohol inhibition of oseltamivir occurs but is not likely to be clinically significant. However, this result cannot be extrapolated to other CES1 substrate drugs. Other substrates such as clopidogrel have additional metabolic pathways that compete with CES1, which should result in the shunting of the drug down an alternate pathway if CES1 hydrolysis is inhibited [42, 43, 53] . As a result, a change in active metabolite formation would be expected [53] . The effects of alcohol inhibition in this situation would be expected to have potentially greater clinical implications than that seen with oseltamivir. We did not determine the CES1 genotype in our subject cohort. Although the CES1 c.428G[A lossof-function polymorphism is associated with reduced oseltamivir hydrolysis in vitro, the variant allele is rare, found in only 0.6-4.0 % of individuals [54, 55] . Moreover, only modest differences in oseltamivir pharmacokinetics between subjects homozygous for the wild-type allele and heterozygous carriers of the loss-of-function polymorphism were identified [56] . Because each subject serves as his/her own control in our study, it is unlikely that the presence of a rare functional variant would influence our findings. Finally, our studies did not assess transporter activity, which could play a role in the effects of alcohol on drug disposition.
Conclusions
Our results show that alcohol significantly inhibits CES1-mediated hydrolysis of oseltamivir but does not affect the hydrolysis of aspirin by CES2. The findings in this study interpreted in the context of the clinical effect of alcohol on two other CES1 substrates, methylphenidate and cocaine, provide strong evidence that alcohol consumed at typical doses can significantly inhibit CES1-mediated drug hydrolysis, resulting in altered disposition of substrate medications, which may subsequently affect their safety and efficacy.
